The NeXuS System is designed to address the underlying structural pathology of degenerative mitral valve disease by implanting artificial chordae through a transcatheter procedure on a beating heart. The objective is to restore mitral valve sufficiency while preserving the motion of the native valve leaflets and annulus.
Transcatheter edge-to-edge repair (TEER) has pioneered catheter-based mitral valve repair as an important therapeutic option for patients with mitral regurgitation. TEER reduces regurgitation by bridging the anterior and posterior mitral valve leaflets but does not preserve the native leaflet function which is desirable in DMR.